Gilead Sciences (GILD) Receives Price Target

Gilead Sciences (GILD) : Currently there are 12 street experts covering Gilead Sciences (GILD) stock. The most bullish and bearish price target for the stock is $122 and $93 respectively for the short term. The average price target of all the analysts comes to $108.92. The estimated standard deviation from the target is $8.82.

Gilead Sciences (GILD) : Zacks Investment Research ranks Gilead Sciences (GILD) as 3, which is a Hold recommendation. 8 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 9 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 18 research analysts is 2.06, which indicates as a Buy.


Also, In the latest statement by the brokerage house, Argus Research downgrades its outlook on Gilead Sciences (NASDAQ:GILD). The current rating of the shares is Hold, according to the research report released by the firm. Previously, the company had a rating of Buy. The rating by the firm was issued on July 29, 2016.

Gilead Sciences (NASDAQ:GILD): The stock opened at $78.43 on Thursday but the bulls could not build on the opening and the stock topped out at $78.46 for the day. The stock traded down to $76.94 during the day, due to lack of any buying support eventually closed down at $77.42 with a loss of -1.22% for the day. The stock had closed at $78.38 on the previous day. The total traded volume was 12,403,880 shares.

Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.